Adequacy of glycemic control in hemodialysis patients with diabetes

Diabetes Care

Volumn 29, Issue 10, 2006, Pages 2247-2251

  Tascona, Daniel J ^a   Morton, A Ross ^a   Toffelmire, Edwin B ^a   Holland, David C ^a   Iliescu, Eduard A ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN A1C; INSULIN; MEGLITINIDE; SULFONYLUREA;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GLYCEMIC CONTROL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROANGIOPATHY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE;

ADULT; AGED; BLOOD GLUCOSE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; ONTARIO; PREVALENCE; RENAL DIALYSIS;

EID: 33845402345     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0845     Document Type: Article

References (21)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
3. Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, Ishimura E, Nishizawa Y: Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 24:909-913, 2001
4. Mak RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 13:4-8, 2000
5. Weykamp CW, Penders TJ, Siebelder CWM, Muskiet FAJ, van der Slik W: Interference of carbamylated and acetylated hemoglobins in assays of glycohemoglobin by HPLC, electrophoresis, affinity chromatography and enzyme immunoassay. Clin Chem 39:138-142, 1993
6. Weykamp CW, Penders TJ, Muskiet FAJ, van der Slik W: Influence of hemoglobin variants and derivatives on glycohemoglobin determinations, as investigated by 102 laboratories using 16 methods. Clin Chem 39:1717-1723, 1993
7. Halwachs-Baumann G, Katzensteiner S, Schnedl W, Purstner P, Pieber T, Wilders-Truschnig M: Comparative evaluation of three assay systems for automated determination of hemoglobin A1c. Clin Chem 43:511-517, 1997
8. Little RR, Tennill AL, Rohlfing C, Wiedmeyer HM, Khanna R, Goel S, Agrawal A, Madsen R, Goldstein DE: Can glycohemoglobin be used to assess glycemic control in patients with chronic renal failure? Clin Chem 48:784-786, 2002
9. Tzamaloukas AH, Murata GH, Zager PG, Eisenberg B, Avasthi PS: The relationship between glycemic control and morbidity and mortality for diabetics on dialysis. ASAIO J 39:880-885, 1993
10. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Canadian Journal of Diabetes 27 (Suppl. 2):S1-S152, 2003
11. American Diabetes Association: Clinical practice recommendations 2005. Diabetes Care 28 (Suppl. 1):S1-S79, 2005
12. Coon P, Zulkowski K: Adherence to American Diabetes Association standards of care by rural health care providers. Diabetes Care 25:2224-2229, 2002
13. Loipl J, Schmekal B, Biesenbach G: Long-term impact of chronic hemodialysis on glycemic control and serum lipids in insulin-treated type 2-diabetic patients. Renal Failure 27:305-308, 2005
14. de Vegt F, Dekker JM, Ruhe HG, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Hyperglycaemia is associated with allcause and cardiovascular mortality in the Hoorn population: the Hoorn study. Diabetologia 42:926-931, 1999
15. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N: Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 322:15-18, 2001
16. Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S: GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes: the Rancho Bernardo Study. Diabetes Care 19:450-456, 1996
17. Nakao T, Matsumoto H, Okada T, Han M, Hidaka H, Yoshino M, Shino T, Yamada C, Nagaoka Y: Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on hemodialysis. Intern Med 37:826-830, 1998
18. Tuzcu A, Bahceci M, Yilmaz E, Bahceci S, Tuzcu S: The comparison of insulin sensitivity in non-diabetic hemodialysis patients treated with and without recombinant human erythropoietin. Horm Metab Res 36:716-720, 2004
19. El-Achkar TM, Ohmit SE, McCullough PA, Crook ED, Brown WW, Grimm R, Bakris GL, Keane WF, Flack JM: Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: the Kidney Early Evaluation Program. Kidney Int 67:1483-1488, 2005
20. Ly J, Marticorena R, Donnelly S: Red blood cell survival in chronic renal failure. Am J Kidney Dis 44:715-719, 2004
21. Joy MS, Cefalu WT, Hogan SL, Nachman PH: Long-term glycemic control measurements in diabetic patients receiving hemodialysis. Am J Kidney Dis 39:297-307, 2002